Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY)

Ocrelizumab is a recombinant humanized monoclonal antibody selectively targeting CD20-expressing B cells. The effect of ocrelizumab on primary progressive multiple sclerosis (PPMS) has been evaluated during phase 3 trials that enrolled patients under 55 years with a maximum Expanded Disability Statu...

Descripción completa

Detalles Bibliográficos
Autores principales: Chisari, Clara G., Bianco, Assunta, Brescia Morra, Vincenzo, Calabrese, Massimiliano, Capone, Fioravante, Cavalla, Paola, Chiavazza, Carlotta, Comi, Cristoforo, Danni, Maura, Filippi, Massimo, Iaffaldano, Pietro, Lanzillo, Roberta, Lo Fermo, Salvatore, Lucisano, Alessandra, Lugaresi, Alessandra, Lus, Giacomo, Marfia, Gerolama Alessandra, Marinelli, Fabiana, Mirabella, Massimiliano, Moiola, Lucia, Perin, Chiara, Realmuto, Sabrina, Toscano, Simona, Trojano, Maria, Vecchio, Domizia, Patti, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684838/
https://www.ncbi.nlm.nih.gov/pubmed/37610702
http://dx.doi.org/10.1007/s13311-023-01415-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684838/
https://www.ncbi.nlm.nih.gov/pubmed/37610702
http://dx.doi.org/10.1007/s13311-023-01415-y

Ejemplares similares